On January 3, 2013, InterMune, Inc. (the "Company") issued a press release announcing preliminary revenue for the quarter ended December 31, 2012. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this current report shall not be deemed to be "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

(d) Exhibits.

Exhibit No.       Description

99.1              Press release "InterMune Reports Preliminary Fourth Quarter 2012
                  Esbriet (Pirfenidone) Revenue and Other Recent Business
                  Highlights" dated January 3, 2013.